论文部分内容阅读
目的 观察雾化吸入注射用重组人粒细胞-巨噬细胞集落刺激因子(GM-CSF)治疗复发性肺泡蛋白沉积症(PAP)的疗效及安全性.方法 对3例确诊PAP并予以大容量全肺灌洗后复发的患者再予以雾化吸入GM-CSF治疗,对比治疗前后临床症状、肺部高分辨CT、肺功能及动脉血氧分压的临床数据,分析其治疗效果.结果 3例患者经过雾化吸入GM-CSF治疗后,临床症状减轻,肺部病变明显减少,动脉血氧分压、肺通气功能和肺弥散功能均明显上升,治疗过程中,3例患者均无不良反应.结论 雾化吸入GM-CSF治疗复发性PAP安全有效,但远期效果还有待进一步观察.“,”Objective To evaluate therapeutic efficacy and safety of recombinant human granulocytemacrophage colony-stimulating factor (GM-CSF) inhalation in patients with recurrent pulmonary alveolar proteinosis (PAP).Methods Three cases of recurrent PAP were treated by GM-CSF inhalation after whole lung lavage.The clinical data of the pulmonary function and SpO2,the clinical symptoms and pulmonary lesions were compared before and after treatment.Results The pulmonary function and manifestations were improved obviously after GM-CSF inhalation.Also the ground-glass opacity was improved in high-resolution CT.The pulmonary function and SpO2 increased obviously after received GM-CSF inhalation.There were no any adverse reactions in 3 cases.Conclusion GM-CSF inhalation therapy is effective and safe in recurrent PAP,but the long-term effect remains to be seen.